Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
12.13
-0.43 (-3.42%)
May 19, 2026, 2:38 PM EDT - Market open
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$211,072
Profits / Employee
-$2,534,761
Market Cap
138.61M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 134 |
| Alps Group | 93 |
| Connect Biopharma Holdings | 64 |
| Korro Bio | 49 |
| Spero Therapeutics | 25 |
| Black Diamond Therapeutics | 21 |
| Galectin Therapeutics | 9 |
| Spruce Biosciences | 8 |
KZIA News
- 4 weeks ago - Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer - TheFly
- 4 weeks ago - Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - PRNewsWire
- 4 weeks ago - Kazia Therapeutics initiated with a Buy at Laidlaw - TheFly
- 5 weeks ago - Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer - TheFly
- 5 weeks ago - Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - PRNewsWire
- 3 months ago - Kazia Therapeutics’ NDL2 shows anti-tumor efficacy in preclinical data - TheFly
- 3 months ago - Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) - PRNewsWire
- 3 months ago - Four new option listings and one option delisting on January 28th - TheFly